We recently demonstrated that CYP3A-mediated drug metabolism is differently affected by early- and late-stage cholestasis and, on these grounds, we suggested that PXR and CAR might be targeted therapeutically to promote CYP3A-mediated liver detoxification [15]. The gene discussed is CYP3A4; the disease is cholestasis.